In addition to pazopanib, two trials suggested the TKI against PDGFR, VEGFR 1–3, c‐KIT, FLT sunitinib to be of clinical benefit in patients with seminomateous or non-seminomateous germ cell tumors refractory to first line therapy. This evidence concerns the gene KIT and testicular germ cell tumor.